News >

Expert Discusses Degarelix and Other Developments in Prostate Cancer

Chelsea LoCascio
Published: Tuesday, Nov 14, 2017

Guru Sonpavde, MD

Guru Sonpavde, MD
The question of when to administer the LHRH receptor antagonist degarelix (Firmagon) to patients with castration-sensitive prostate cancer versus an agonist still remains to be answered, according to Guru P. Sonpavde, MD.

on Genitourinary Cancers, Sonpavde, director of Bladder Cancer at the Dana-Farber Cancer Institute, discussed degarelix, androgen-deprivation therapy (ADT), and ongoing trials with immunotherapy that are crucial to advancing the treatment of patients with prostate cancer.

OncLive: What did you focus on in your presentation on prostate cancer?

Sonpavde: In the talk, I focused on degarelix, which is an LHRH receptor antagonist as opposed to the LHRH agonists that are in use for a longer time. Essentially, the data right now for degarelix are that this drug suppresses testosterone more rapidly and might have some benefit in patients with a history of cardiovascular events. It seems like patients who have had cardiovascular events might have fewer cardiovascular events on degarelix as opposed to LHRH agonists. There might also be a benefit in terms of prostate-specific antigen progression-free survival, but we’re not quite sure about the efficacy yet because these trials were not designed to look at efficacy as the primary endpoint.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication